Erosion induced controllable release of gliclazide encapsulated inside degradable polymeric particles.
The microphase inversion of water-insoluble poly(L-lactide), "poly[(L-lactide)-co-glycolide] and polylactide-block-poly(ethylene oxide)-block-polylactide from THF to water can result in narrowly distributed stable particles. Gliclazide, a commercial drug, can be encapsulated inside during the process. The formation and degradation of such particles was studied by laser light scattering. In comparison with the corrosion of a bulk material, the degradation of each particle is so fast that we only detect the decrease of the particle number, not the corrosion of individual particles. Therefore, the degradation is a "one-by-one" random process, just like the chemical reaction of molecules in solution. The disappearing rate of the particle number is nearly independent of time, ideal for the controlled release of drugs encapsulated inside. The amount of encapsulated gliclazide depends on the copolymer's hydrophobicity (composition), while the releasing rate mainly is, directly related to the disappearing rate of the particles. The correlation between the fluorescence intensity and the degradation was used to study the kinetics of gliclazide releasing. The releasing pattern is controllable with a proper choice of the drug loading, copolymer composition, pH and temperature.
Zhao
Yue
Y
The Open Laboratory of Bond-selective Chemistry, Department of Chemical Physics, University of Science and Technology of China, Hefei, Anhui, 230026, China.
Chen
Wenna
W
Cai
Qing
Q
Wang
Shenguo
S
Bo
Jun
J
Wu
Chi
C
D001673:Biodegradation, Environmental; D002214:Capsules; D003692:Delayed-Action Preparations / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism; D004852:Epoxy Compounds / Q000737:chemistry; D005907:Gliclazide / Q000008:administration & dosage* / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000737:chemistry; D011091:Polyesters / Q000737:chemistry* / Q000378:metabolism; D011098:Polyglactin 910 / Q000737:chemistry
D002214:Capsules; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004852:Epoxy Compounds; D007004:Hypoglycemic Agents; C402662:PEO-poly(lactide); D011091:Polyesters; D011098:Polyglactin 910; C033616:poly(lactide); D005907:Gliclazide